Brief: Galera Reports Third Quarter 2022 Financial Results
Nov 9 (Reuters) - Galera Therapeutics Inc GRTX.O :
* GALERA REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND
RECENT
CORPORATE UPDATES
* GALERA THERAPEUTICS INC Q3 LOSS PER SHARE $0.60
* ON TRACK TO SUBMIT NDA TO U.S. FDA FOR AVASOPASEM BY END
OF 2022
* AS OF SEPTEMBER 30, 2022, CO HAD CASH, CASH EQUIVALENTS
AND
SHORT-TERM INVESTMENTS OF $42.8 MILLION
* CO EXPECTS EXISTING CASH, CASH EQUIVALENTS & SHORT-TERM
INVESTMENTS WILL ENABLE CO TO FUND OPERATING EXPENSES & CAPEX
REQUIREMENTS INTO H2 OF 2023
Source text for Eikon: ID:nGNX6j9Nxk
Further company coverage: GRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Galera Therapeutics
See all newsBrief: Galera Therapeutics Says Nasdaq Will Delist Co's Common Stock By Filing Form 25 With SEC On Sept 4
Brief: Galera Announces Board Approval Of Complete Liquidation And Dissolution
Brief: Galera Therapeutics Receives Written Notice From Nasdaq Indicating That Nasdaq Hearings Panel Determined To Delist Co’s Shares
Brief: Alpha Pharma Investments Llc Reports 10.899% Passive Stake In Galera Therapeutics
Brief: Galera Adopts Limited Duration Stockholder Rights Agreement